Tune & Track
Affinity Tuned CAR T Cells for Solid Tumors
Unlocking the Full Potential of CAR T Cell Therapies
AffyImmune is harnessing the power of the body’s own immune system to seek and destroy cancer cells by overcoming the immunotherapy challenges for solid tumors. AffyImmune’s proprietary “Tune & Track” technology enhances the ability of a patient’s own immune cells to attack and destroy solid tumors, while avoiding damage to normal cells and tissues.
FEATURED NEWS
FEATURED JOBS
AffyImmune Therapeutics Adds Serial Entrepreneur Robert Forrester to Board of Directors
NATICK, Mass. (SEPTEMBER 29, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, announced today that serial biotech entrepreneur Robert Forrester has been appointed to its [...]